Usa Netherlands covid-19 vaccine infection Coronavirus Usa Netherlands

Intravacc and EpiVax to develop Covid-19 vaccine candidate

Reading now: 686
www.pharmaceutical-technology.com

Dutch research and development vaccine institute Intravacc has partnered with US-based biotechnology firm EpiVax to advance a Covid-19 vaccine candidate.

The vaccine is based on Intravacc’s Outer Membrane Vesicles (OMV) platform. Under the collaboration agreement, Intravacc’s immunogenic OMV delivery platform will unite with EpiVax’s synthetically generated Covid-19 epitopes designed and optimised using immunoinformatics tools.

The aim is to produce a safe and effective T-cell response against SARS-CoV-2 and other related coronaviruses. Our parent business intelligence company EpiVax CEO and CSO Annie De Groot said: “We are thrilled to enter into a partnership with Intravacc using their very novel ‘click-on’ OMV technology and the

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA